Podcasts about Pharmacology

Fluphenazine is a high-potency typical antipsychotic that primarily acts as a dopamine D2 receptor antagonist in the mesolimbic pathway, reducing positive symptoms of schizophrenia. Extrapyramidal symptoms (EPS), such as dystonia, akathisia, and parkinsonism, are common due to potent D2 blockade in the nigrostriatal pathway. Neuroleptic malignant syndrome (NMS), though rare, is a life-threatening adverse effect characterized by rigidity, hyperthermia, altered mental status, and autonomic instability. CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can increase fluphenazine plasma concentrations, potentially raising the risk of toxicity and side effects. Concomitant use of fluphenazine with CNS depressants (e.g., alcohol, benzodiazepines) can enhance sedation and respiratory depression.

Episode 367: Pharmacology 101: PARP Inhibitors “We know that in cells that are proliferating very quickly, including cancer cells, single-strand DNA breaks are very common. When that happens, these breaks are often repaired by the PARP enzyme, and the cells can continue their replication process. If we block PARP, that repair cannot happen. So in blocking that, these single-strand breaks then lead to double-strand breaks, which ultimately is leading to cell apoptosis,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the PARP inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 13, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the use of PARP inhibitors in cancer care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 232: Managing Fatigue During PARP Inhibitor Maintenance Therapy Episode 227: Biomarker Testing, PARP Inhibitors, and Oral Adherence During Ovarian Cancer Maintenance Therapy ONS Voice articles: PARP Inhibitors and Ovarian Cancer Genomics May Trick PARP Inhibitors to Treat More Cancers Oncology Drug Reference Sheet: Niraparib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing articles: PARP Inhibition: Genomics-Informed Care for Patients With Malignancies Driven by BRCA1/BRCA2 Pathogenic Variants Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers Oncology Nursing Forum article: Familiarity and Perceptions of Ovarian Cancer Biomarker Testing and Targeted Therapy: A Survey of Oncology Nurses in the United States Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Biomarker Database ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The big toxicities here to watch for are primarily hematologic toxicities. It is one of those targeted therapies that does affect blood cell counts. So I'd say the blood cell count that is most commonly affected here is the hemoglobin. So, anemia very frequent complication that we see, probably a little bit more with olaparib compared with other drugs, but we see it as a class side effect. And we can also see neutropenia and thrombocytopenia with these agents, probably a little bit more with niraparib versus the others, but again, you can see it across all of these drugs.” TS 8:16 “We mentioned that rare risk of MDS and AML. This isn't a particularly scary thing if you talk to patients about it. Because of the rarity that we see this, it isn't something that we need to overemphasize, but I think careful monitoring of blood counts in is stressing the importance of that and early intervention here is very important.” TS 16:55 “This is a collaborative effort. And because of the home administration here, these patients do need to be followed very closely. So we are not laying eyes on them usually with the frequency that we do when we have patients actually coming into our infusion centers for treatments—so making sure that there is a plan for regular follow-up with these patients to ensure that they're getting that lab work done, that that's being looked at closely, that we're adjusting the dose if we need to based on that lab work, that we are managing the patient's fatigue. Again, that potentially dose reductions may be needed if patients are having that extreme fatigue.” TS 19:34 “I think one of those [misconceptions] could be that they're only effective in patients that have that BRCA1/2 mutation. And again, remember here that there is some data in particular disease states that we can use them and that they work in the absence of those mutations.” TS 25:12

Every other week I'm republishing one of my most popular or impactful episodes and adding an update, new insight, or context that will help you benefit from it even more. This week I'm highlighting Episode 116, which is all about pediatric pharmacology. When you understand these key foundation concepts, the whole subject of pharm gets a whole lot easier. Enjoy! As cute and adorable as they are, kids are not just tiny adults. Especially when it comes to pharmacology. The way kids absorb, distribute, metabolize and excrete drugs varies greatly, making pediatric pharmacology a truly unique subject.  If you're heading into your pediatric rotation or starting out as a new pediatric RN, then pop in those earbuds. I'll talk you through the key things you need to know to utilize medications safely in this very special and vulnerable population.  ___________________ ⁠Full Transcript⁠ - Read the article and view references ⁠FREE CLASS⁠ - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! ⁠Dosage Calculations Guide⁠ - Kick math anxiety to the curb and learn the basics of how to set up and perform dosage calculations using dimensional analysis with this FREE guide. Includes 10 free practice questions! ⁠Pharmacology Success Pack⁠ - Want to get a head start on pharmacology? Download the FREE Pharmacology Success Pack.  ⁠Fast Pharmacology⁠ - Learn pharmacology concepts in 5 minutes or less in this audio based program. Perfect for on-the-go review! ⁠Straight A Nursing App⁠ - Study on-the-go with the Straight A Nursing app! Review more than 5,000 flashcards covering a wide range of subjects including Fundamentals, Pediatrics, Med Surg, Mental Health, Maternal Newborn, and more! Available for free in the Apple App Store and Google Play Store.

On this podcast episode, I discuss quinapril pharmacology, adverse effects, drug interactions, pharmacokinetics, and much more. Quinapril is a prodrug that is converted in the liver to its active metabolite, quinaprilat, which inhibits ACE, leading to decreased formation of angiotensin II and reduced aldosterone secretion. Hyperkalemia can occur with quinapril use due to decreased aldosterone, leading to potassium retention—especially in patients with renal impairment. Concomitant use of potassium-sparing diuretics or potassium supplements with quinapril increases the risk of hyperkalemia. NSAIDs may reduce the antihypertensive effect of quinapril and increase the risk of nephrotoxicity, especially in patients with preexisting renal dysfunction.

GLP-1 receptor agonists have changed the landscape of obesity treatment, offering levels of weight loss once thought unattainable without surgery. But what happens after the weight is lost? And can we really talk about success without talking about maintenance? While much of the public discourse fixates on dramatic weight loss numbers, the harder question is what comes next. Can lifestyle interventions alone sustain weight loss after GLP-1 cessation? How do metabolic adaptations and behavioral relapse factor in? And what does the data actually show about relapse rates, nutritional adequacy, and lean mass preservation when using these medications? In this episode, Danny sits down with Tara Schmidt, dietitian at the Mayo Clinic, to examine the intersection of pharmacology and behavior in long-term weight management. Tara Schmidt is a registered dietitian and an instructor of nutrition at Mayo Clinic. As the lead dietitian for the Mayo Clinic Diet, she provides guidance rooted in evidence-based principles. She hosts the Mayo Clinic On Nutrition podcast and co-authored The Mayo Clinic Diet: Weight Loss Medications Edition. Timestamps [05:17] Understanding weight loss maintenance [08:44] Defining success in weight loss maintenance [11:54] Predictors of maintenance: self-monitoring and behavioral strategies [23:37] Pharmacological interventions: GLP-1 receptor agonists [31:06] Dietary considerations for those taking GLP-1 RAs [37:07] Addressing misconceptions about weight loss drugs [42:48] Final thoughts and takeaways [48:49] Key ideas (Premium-only) Links/Resources Subscribe to Sigma Nutrition Premium Go to episode page Join the Sigma email newsletter for free Enroll in the next cohort of our Applied Nutrition Literacy course Visit sigmanutrition.com

Behavioral Health Integration in Pediatric Care with Dr. Nelson BrancoIn this episode of The Pediatric Lounge, hosts George and Herb are joined by Dr. Nelson Branco, a general pediatrician with a strong commitment to behavioral health and community care, to discuss the future of healthcare and the integration of behavioral health into pediatric medical homes. Dr. Branco shares his journey in pediatrics, his experience working with underserved populations, and the steps his practice took to integrate behavioral health services. The conversation covers the challenges and benefits of behavioral health integration, the importance of collaboration with therapists and psychiatrists, and strategies for managing financial sustainability. The episode also delves into the impact of mental health on pediatricians' burnout and the evolving role of pediatric care in addressing behavioral health concerns.00:00 Introduction to The Pediatric Lounge00:36 Meet Dr. Nelson Branco01:16 Dr. Bronco's Journey to Pediatrics03:00 Behavioral Health Integration in Pediatrics03:54 Building a Behavioral Health Team05:32 Challenges and Realities of Behavioral Health07:26 Innovative Solutions and Collaborations10:17 The Evolution of Pediatric Care25:24 Pharmacology and Changing Practices28:56 Training and Preparedness for Physicians29:39 Virginia Mental Access Program and Project Echo30:34 Challenges in Child Psychiatry31:21 Primary Care Mental Health Experience36:49 Operations and Management in Pediatric Practices42:16 Behavioral Health Integration and Financial Sustainability45:11 Burnout and Mental Health in Pediatricians52:51 Historical Perspective on Pediatric Practice55:18 Preventative Behavioral Health and ConclusionDr. Branco has kindly shared his folder on Mental Health in Pediatrics, which is an incredible resource: https://bit.ly/BHIshared.Support the show

Nifedipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance. The extended-release formulation of nifedipine provides more stable plasma concentrations and is preferred for chronic management of hypertension and angina. Common adverse effects include headache, flushing, peripheral edema, and dizziness, all related to its vasodilatory action. Nifedipine undergoes extensive first-pass metabolism in the liver, primarily via CYP3A4 enzymes, which significantly influences its bioavailability and potential drug interactions. CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice) can increase plasma levels of nifedipine, raising the risk of hypotension and adverse effects.

On this episode, we evaluate current guidelines and evidence-based treatment strategies for managing GAD. We define generalized anxiety disorder (GAD) and describe its clinical presentations, diagnostic criteria, and underlying pathophysiology. We also compare and contrast the efficacy, safety profiles, and appropriate use of anxiolytic medications, cognitive behavioral therapy, and lifestyle modifications in treating GAD. Dr. David Osser's Website: https://psychopharm.mobi/algo_live/ Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

In this episode, CancerNetwork® spoke with Eric Winer, MD,  director of the Yale Cancer Center; president and physician-in-chief at Smilow Cancer Hospital; deputy dean for cancer research, Alfred Gilman Professor of Pharmacology, and Professor of Medicine at Yale School of Medicine; and chair of the association board for the American Society of Clinical Oncology (ASCO), about the current state of oncologist burnout, steps that can be taken to ameliorate it, and how it currently impacts professionals in the field. Causes of workplace burnout that authors identified in a paper published in the Journal of Clinical Oncology in January 2025 included the use of electronic health records, staffing levels, payer authorizations, hours worked, and age. Additionally, published results from the survey revealed a 14% increase in the rate of oncologists who experienced workplace burnout from 2013 to 2023 (P

On this podcast episode, I discuss Clotrimazole pharmacology, adverse effects, indications, administration, and much more. Clotrimazole is an imidazole antifungal that exerts its pharmacological effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes. This inhibition compromises membrane integrity, leading to leakage of cellular contents and ultimately fungal cell death. Clotrimazole is primarily used topically due to poor systemic absorption when administered via the skin or mucous membranes, which limits systemic side effects. When clotrimazole is used intravaginally or orally in lozenge form, localized concentrations are sufficient to treat mucocutaneous infections without significant systemic exposure. Pay attention when clotrimazole is used frequently to treat Candida infections as corticosteroids, immunosuppression, and antibiotics may increase the risk of this type of infection.

Dr. Alipi Bonm, a neuro-oncologist at the Providence Swedish Cancer Institute in Seattle, joins host Dr. Ashwani Rajput to offer up valuable insights into brain cancer, from what to expect to the promising treatment options available that could ease your fears. He also debunks common myths, such as the misconception that cell phones and electrical wires cause brain cancer and highlights promising future treatments. If you or a loved one are affected by brain cancer, discover the support groups available for both patients and caregivers. Don't miss out on this informative and supportive discussion.Dr. Ashwani Rajput BioSee below Do you want to know more?Check out the Providence blog for more information on melanoma and other cancer related topics. Personalized cancer peptide vaccine shows remarkable promise against glioblastomaProvidence Saint John's opens last phase of clinical trial of promising drug for aggressive brain cancerTo learn more about our mission programs and services, go to Providence.org.Follow us on social media to get continued information on other important health care topics. You can  connect with us on LinkedIn, Facebook, TikTok, Instagram and X.For all your healthcare information on the go, download the Providence app. Whether you're tracking symptoms, scheduling appointments, or connecting with your healthcare providers, the Providence app has your back.To learn more about the app, check out the Wellness Brief podcast episode. Wellness Brief: Simplifying Care-There's an App for That.We'd love to hear from you. You can contact us at FutureOfHealthPodcasts@providence.org Dr. Ashwani Rajput BioAshwani Rajput, MD, FACS, joined Providence Swedish in September 2024 as the regional executive medical director (EMD) of the Swedish Cancer Institute. Dr. Rajput comes to us from Johns Hopkins University, where he is a professor of Surgery and Oncology, as well as the director of the Hopkins Kimmel Cancer Center in the Washington, D.C. region. Dr. Rajput completed his medical school, general surgery training, and a post-doctoral fellowship in molecular genetics at Case Western Reserve University in Cleveland, Ohio. He went on to the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., for a fellowship in Complex General Surgical Oncology (CGSO). There, he was recruited to join the faculty at Roswell Park with appointments in GI Surgical Oncology as well as Pharmacology and Therapeutics. His laboratory investigated the key signal transduction pathways in colorectal metastases using novel orthotopic murine models. In 2009, Dr. Rajput was recruited to the University of New Mexico as the inaugural division chief of Surgical Oncology. During his tenure in New Mexico, he also served as the director of surgical services for the NCI-designated Comprehensive Cancer Center and vice-chair of surgery for academic affairs and faculty development. Under his leadership, an ACGME-approved fellowship in CGSO was created and launched. Throughout his roles in New Mexico and D.C., he has actively addressed cancer health care outcomes and health equity. Under Dr. Rajput's leadership, he will develop and implement a cancer strategic vision and enhance collaboration across our geography. He will oversee the SCI medical directors and partner with the Senior Director of Operations to deliver excellence in cancer care. Dr. Rajput and his wife, Sunita, have four children. Outside of work, he enjoys playing tennis, piano, the arts, and traveling.

Donate for chronic fatigue and long COVID research today. https://givenow.nova.edu/donations-for-chronic-fatigue-and-long-covid-research/?a=4951638  In this episode, Haylie Pomroy speaks with Dr. Theoharis Theoharides about the physiological consequences of stress on the body. They discuss how stress impacts the immune system, including its role in both anti-inflammatory and pro-inflammatory responses. Dr. Theoharides explains how mast cells are involved in the body's stress response, the symptoms of mast cell activation, and how to recognize if someone may be experiencing chronic issues. He also shares practical steps to identify when stress is not being managed well and highlights the importance of nutrition and lifestyle in recovery. Tune in to the Hope and Help for Fatigue and Chronic Illness Podcast – The Physiological Consequences of Chronic Stress Sign up for the COVID-UPP Study: https://redcap.nova.edu/redcap/surveys/?s=RMEDJ7LKCX&_gl=1*1h830h7*_gcl_au*MTM2NDA0MTQyOS4xNzE1MDA0ODAy If you are interested in joining a Gulf War Illness (GWI) trial, please complete the Recruitment Registry Form. https://redcap.nova.edu/redcap/surveys/?s=Y9YF8JJWJRK8HEKL%20&_gl=1*1fipp18*_gcl_aw*R0NMLjE3MDc5MTgwMzIuRUFJYUlRb2JDaE1JeWNyUXVfcXFoQU1WU1pCYUJSM3AyQWRBRUFBWUFTQUFFZ0s1NWZEX0J3RQ..*_gcl_au*MTg2NjgwMDQ4Ni4xNzA3MTQwNzgx  Learn more about INIM's Research Studies: https://www.nova.edu/nim/research-studies/index.html Read INIM's latest publication. https://pubmed.ncbi.nlm.nih.gov/40332133/ Dr. Theoharis Theoharides is Professor and Vice Chair of Clinical Immunology and Director at the Institute for Neuro-Immune Medicine–Clearwater. He is also Adjunct Professor of Immunology at Tufts School of Medicine, where he previously served as Professor of Pharmacology and Internal Medicine, and Director of Molecular Immunopharmacology & Drug Discovery. He earned multiple advanced degrees (BA, MS, MPhil, PhD, MD) from Yale University, received a Certificate in Global Leadership from Tufts Fletcher School, and completed a fellowship at Harvard Kennedy School. With over 485 publications and an h-index of 106, he ranks among the top 2% of most-cited researchers and was named the leading global expert on mast cells by Expertscape. His honors include induction into Alpha Omega Alpha, the Rare Diseases Hall of Fame, and the World Academy of Sciences. Website: https://www.drtheoharides.com  LinkedIn: linkedin.com/in/theoharis-theoharides-ms-phd-md-faaaai-67123735   Instagram: https://www.instagram.com/dr.theoharides Haylie Pomroy, Founder and CEO of The Haylie Pomroy Group, is a leading health strategist specializing in metabolism, weight loss, and integrative wellness. With over 25 years of experience, she has worked with top medical institutions and high-profile clients, developing targeted programs and supplements rooted in the "Food is Medicine" philosophy. Inspired by her own autoimmune journey, she combines expertise in nutrition, biochemistry, and patient advocacy to help others reclaim their health. She is a New York Times bestselling author of The Fast Metabolism Diet. Website: https://hayliepomroy.com/podcast Instagram: https://www.instagram.com/hayliepomroy  Facebook: https://www.facebook.com/hayliepomroy  LinkedIn: https://www.linkedin.com/in/hayliepomroy/  X: https://x.com/hayliepomroy  TikTok: https://tiktok.com/@hayliepomroy Enjoy our show? Please leave us a 5-star review so we can bring hope and help to others. Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d Learn more about the Institute here. Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM

Irbesartan is an angiotensin II receptor blocker (ARB) used primarily for the management of hypertension and diabetic nephropathy in type 2 diabetes. It selectively inhibits the binding of angiotensin II to the AT1 receptor found in vascular smooth muscle and the adrenal gland. This blockade results in vasodilation, reduced aldosterone secretion, decreased sodium and water retention, and ultimately lower blood pressure. Irbesartan is administered orally, with a typical starting dose of 150 mg once daily, which may be increased to 300 mg depending on the patient's clinical response and tolerability. Adverse effects of irbesartan are generally mild but can include hyperkalemia and dizziness. Hypotension may occur, especially in volume-depleted individuals or those on diuretics. Routine monitoring of renal function and serum potassium is recommended, especially in patients with underlying kidney disease or those taking potassium-sparing agents or supplements. Irbesartan is contraindicated in pregnancy due to the risk of fetal toxicity and should be discontinued as soon as pregnancy is detected.

On this week's show, your host, Justin Mog, scrubs your aural environment of all toxins with two colleagues from the University of Louisville's Center for Integrative Environmental Health Science (CIEHS): Cat Aiton, MSW, is the Community Resource Coordinator for the Community Engagement Core of CIEHS, and Sarah Jump is the Communications & Marketing Specialist. Learn more about the Center at https://louisville.edu/ciehs On the show, we discuss what environmental health is and how we all play a role in either advancing it or detracting from it. We share some practical tips for keeping yourself, your family, and your entire community healthy in the face of a world of dangerous toxins and pollutants. We talk about how the Center is working to reach young people with empowering messages and walking the talk with more sustainable give-aways. You'll also learn about an upcoming Conference for Advancing Participatory Sciences and the importance of Report Back strategies for sharing findings with communities in a language that is meaningful to them. We'll also tell you all about the upcoming Environmental Health Youth Academy that the Center is organizing this summer (https://events.louisville.edu/event/2025-ciehs-cec-environmental-health-summer-youth-academy). The deadline to apply for this free summer series in June 16th and it is open to all high school sophomores, juniors, and seniors. CIEHS will host a two-week Youth Academy focused on environmental health in Louisville, July 14-24! At the end of the academy, participants will receive a certificate and a letter of completion (plus some free sustainable swag), making this a valuable addition to college or job applications. We have limited spots available—only 20 students will be accepted for this exclusive summer program, where you will learn directly from environmental health experts. Applications must be submitted by June 16th! Learn more and apply at https://louisville.edu/ciehs. The schedule for the Youth Academy is as follows: July 14 (In Person with lunch): Introduction to Environmental Health Banrida Wahlang, PhD, UofL Gastroenterology, Hepatology and Nutrition Lu Cai, MD, PhD, UofL Pediatrics, Radiation Oncology, and Pharmacology & Toxicology July 15 (Virtual): Air Quality and Health Petra Haberzettl, PhD, UofL Medicine, Diabetes & Obesity Center July 16 (Virtual): Water & Health Mayukh Banerjee, PhD, UofL Pharmacology & Toxicology July 17 (In Person with lunch): Community-Led Science Ted Smith, PhD, UofL Medicine and Pharmacology/Toxicology Rachel Neal, PhD, UofL Biology Luz Huntington-Moskos, PhD, RN, CPN, FAAN, UofL School of Nursing July 21 (Virtual): Energy & Health Sumedha Rao, Mayor's Office of Sustainability July 22 (Virtual): Mapping the Issues Charlie Zhang, PhD, UofL Geographic & Environmental Sciences, DJ Biddle, Director and Senior Lecturer, UofL Center for Geographic Information System Laura Krauser, UofL's Geographic Information Sciences Research Coordinator July 23 (Virtual): Communicating Sustainability Brent Fryrear, UofL Sustainability Council July 24 (In Person with lunch): Policy Advocacy and Storytelling Dr. Tony Arnold, UofL Law, Urban and Public Affairs, Resilience Justice Project Angela Story, PhD, UofL Anthropology and Director of Anne Braden Institute As always, our feature is followed by your community action calendar for the week, so get your calendars out and get ready to take action for sustainability NOW! Sustainability Now! is hosted by Dr. Justin Mog and airs on Forward Radio, 106.5fm, WFMP-LP Louisville, every Monday at 6pm and repeats Tuesdays at 12am and 10am. Find us at http://forwardradio.org The music in this podcast is courtesy of the local band Appalatin and is used by permission. Explore their delightful music at http://appalatin.com

Join us for the inaugural episode of "TWAD: Cancer, Cures and Coffee" with Dr. Ashwani Rajput and special guest Dr. Kelly Paulson. In this episode, we dive deep into the topic of Melanoma, one of the most serious types of skin cancer. Dr. Paulson, a medical oncologist at Swedish Cancer Institute First Hill in Seattle, shares her expertise on the importance of early detection, risk factors, and the latest advancements in treatment. Learn how to protect yourself and your loved ones from Melanoma and discover the role of the immune system in fighting cancer. Don't miss this informative and engaging discussion.Dr. Ashwani Rajput BioSee below Do you want to know more?Check out the Providence blog for more information on melanoma and other cancer related topics. ·       Cancer survivor speaks with doctor he credits for saving his life·       Saint Patrick HealthBreak - Skin Cancers·       A year to remember: Advancements, recognition and transitions To learn more about our mission programs and services, go to Providence.org.Follow us on social media to get continued information on other important health care topics. You can  connect with us on LinkedIn, Facebook, TikTok, Instagram and X.For all your healthcare information on the go, download the Providence app. Whether you're tracking symptoms, scheduling appointments, or connecting with your healthcare providers, the Providence app has your back.To learn more about the app, check out the Wellness Brief podcast episode. Wellness Brief: Simplifying Care-There's an App for That. We'd love to hear from you. You can contact us at FutureOfHealthPodcasts@providence.org Dr. Ashwani Rajput BioAshwani Rajput, MD, FACS, joined Providence Swedish in September 2024 as the regional executive medical director (EMD) of the Swedish Cancer Institute. Dr. Rajput comes to us from Johns Hopkins University, where he is a professor of Surgery and Oncology, as well as the director of the Hopkins Kimmel Cancer Center in the Washington, D.C. region. Dr. Rajput completed his medical school, general surgery training, and a post-doctoral fellowship in molecular genetics at Case Western Reserve University in Cleveland, Ohio. He went on to the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., for a fellowship in Complex General Surgical Oncology (CGSO). There, he was recruited to join the faculty at Roswell Park with appointments in GI Surgical Oncology as well as Pharmacology and Therapeutics. His laboratory investigated the key signal transduction pathways in colorectal metastases using novel orthotopic murine models. In 2009, Dr. Rajput was recruited to the University of New Mexico as the inaugural division chief of Surgical Oncology. During his tenure in New Mexico, he also served as the director of surgical services for the NCI-designated Comprehensive Cancer Center and vice-chair of surgery for academic affairs and faculty development. Under his leadership, an ACGME-approved fellowship in CGSO was created and launched. Throughout his roles in New Mexico and D.C., he has actively addressed cancer health care outcomes and health equity. Under Dr. Rajput's leadership, he will develop and implement a cancer strategic vision and enhance collaboration across our geography. He will oversee the SCI medical directors and partner with the Senior Director of Operations to deliver excellence in cancer care. Dr. Rajput and his wife, Sunita, have four children. Outside of work, he enjoys playing tennis, piano, the arts, and traveling.

On this episode, we discuss chronic coronary syndrome (CCS) and describe its clinical presentation, underlying pathophysiology, and progression. We review current guidelines and evidence-based treatment strategies for managing CCS, including both pharmacological and non-pharmacological interventions. Our primary pharmacotherapy focus was on comparing and contrasting antianginal therapies, but we also touch on antiplatelet agents, and risk factor modification strategies. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

On this episode, I discuss benzonatate pharmacology, adverse reactions, and much more. Tessalon Pearls (benzonatate) are a non-narcotic antitussive commonly prescribed to relieve dry, non-productive coughs. Benzonatate acts by numbing stretch receptors in the respiratory tract, lungs, and pleura, which helps suppress the cough reflex at its source. Unlike opioid-based cough suppressants, it doesn't work in the brain's cough center. The usual adult dose is 100 to 200 mg taken orally three times a day as needed, with a maximum daily dose of 600 mg. One of the most critical points is that the capsules must be swallowed whole. Chewing, sucking, or crushing them can cause numbness in the mouth and throat, leading to a risk of choking or aspiration. There are no major drug interactions associated with benzonatate.

Send us a textEpisode Summary: New research on how dietary fats, particularly omega-6 fatty acids like linoleic acid, influence triple-negative breast cancer progression by activating the mTOR pathway, a key regulator of cell growth; role of the FABP5 protein in enhancing cancer cells' sensitivity to omega-6 fats; differences between breast cancer subtypes; broader implications of dietary balance for health.About the guest: John Blenis, PhD is a Professor of Pharmacology at the Meyer Cancer Center at Weill Cornell Medicine. Nikos Koundouros, PhD is a postdoctoral fellow in Blenis' lab.Note: Podcast episodes are fully available to paid subscribers on the M&M Substack and everyone on YouTube. Partial versions are available elsewhere. Transcript and other information on Substack.Key  Points:mTOR pathway acts as a cellular “brain,” sensing nutrients like amino acids, glucose, and fats to regulate growth. Its dysregulation can drive cancer.High dietary omega-6 fatty acids, like linoleic acid found in seed oils, can fuel triple-negative breast cancer growth by activating mTOR.FABP5, a lipid chaperone protein, is overexpressed in triple-negative breast cancer, making these tumors more sensitive to omega-6 fats, suggesting its potential as a therapeutic target.Modern diets with high omega-6 to omega-3 ratios disrupt inflammation balance, unlike historical 1:1 ratios, potentially increasing cancer risk.Genetic variations and cancer subtypes highlight the need for tailored dietary recommendations, as blanket nutrition advice may not suit all patients.While omega-6 fats exacerbate existing triple-negative breast cancer, their role in initiating cancer remains unclear, requiring further study.High omega-6 intake may influence other cancers (e.g., prostate, colon) and chronic diseases like obesity, linked to FABP5 and inflammation.Related episode:M&M 200: Dietary Fats & Seed Oils in Inflammation, Colon Cancer & Chronic Disease | Tim Yeatman & GaneSupport the showAll episodes, show notes, transcripts, and more at the M&M Substack Affiliates: KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off Readwise: Organize and share what you read. 60 days FREE through link Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off For all the ways you can support my efforts

“The signaling and that binding of the MET and the HGF help, in a downstream way, lead to cell proliferation, cell motility, survival, angiogenesis, and also invasion—so all of those key cancer hallmarks. And because of it being on an epithelial cell, it's a really good marker because it's found in many, many different types of cancers, so it makes it what we call kind of a nice actionable mutation,” ONS member Marianne Davies, DNP, ACNP, AOCNP®, FAAN, senior oncology nurse practitioner at Yale Comprehensive Cancer Center in New Haven, CT, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the MET inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 9, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to MET inhibitors. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Capmatinib Oncology Drug Reference Sheet: Tepotinib Predictive and Diagnostic Biomarkers: Identifying Variants Helps Providers Tailor Cancer Surveillance Plans and Treatment Selection ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) Telephone Triage for Oncology Nurses (third edition) ONS courses: Safe Handling Basics ONS Biomarker Database ONS Huddle Cards: Monoclonal Antibodies Targeted Therapy ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets IV Chemotherapy Education Sheets Drugs@FDA To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The MET receptor was actually identified back in 1984. And it was actually identified as an oncogene in osteosarcoma. And so basically what that MET receptor does—it's a tyrosine kinase pathway, and the ligand that it attaches to is something called HGF/SF. That's hepatocyte growth factor/scatter factor. And so this MET pathway tyrosine kinase pathway is really important in tumor cell growth and migration. And it's expressed specifically on epithelial cells, so that's going to really help us in identifying how it can be a pathway for cancer treatments.” TS 1:35 “But in the particular classes, there kind of are some unique things that are with these MET inhibitors. For example, crizotinib, we found early on, causes some vision changes. Patients would report things like floaters or a little bit of blurry vision. For the capmatinib, things like elevation of amylase and lipase, fluid retention and bloating, and hypersensitivity reactions and photosensitivity.” TS 7:36 “Other things to teach for the TKI is the self-management strategies in terms of nausea management and dietary changes for the risk of peripheral edema. Having them do things like maybe doing daily weights, or at least weights every other day, and sometimes doing limb measurements so it can help us really quantify the amount of fluid retention they have. And then from a nursing perspective, meeting with these patients, is to do really good skin inspection. When people have peripheral edema, they're at risk for skin breakdown, and that can lead obviously to infection.” TS 16:06 “The biggest [misconception] is that people assume that all MET mutations are going to be equally responsive to the same targeted therapies, that all of the abnormalities are the same and react the same, and they really don't. We're really diving down and carving that pie thinner and thinner in terms of each individual MET abnormality, in terms of what drugs responds it to and what that means for patient outcomes and prognosis.” TS 25:21

On this episode of the Real Life Pharmacology podcast, I discuss Miralax (polyethylene glycol) pharmacology, adverse effects, and much more. MiraLAX is an osmotic laxative commonly used to treat occasional constipation by retaining water in the stool to increase stool frequency and soften consistency. The standard adult dose of MiraLAX is 17 grams (approximately one heaping tablespoon) dissolved in 4 to 8 ounces of liquid once daily. Electrolyte imbalances are rare but possible with prolonged or excessive use of Miralax, particularly in elderly or renal-impaired patients. Advise patients to maintain adequate hydration while using MiraLAX to support its mechanism and reduce side effects.

In this piece we discuss perioperative medicine with Alana Flexman, an anaesthetist and researcher from Vancouver, Canada, and Maryanne Balkin, an anaesthetist and law graduate from Melbourne, Australia. We explore our guests' career journeys, and gender and equity issues, including unconscious bias and bullying, harassment, and discrimination, in the workplace. Finally we talk about the craziness and joy of continued learning and enquiry. Presented by Andy Cumpstey and Kate Leslie on location at the Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine in Cairns, Australia, with their guests, Dr Alana Flexman, Clinical Associate Professor, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, and St. Paul's Hospital/Providence Health Care, Vancouver, Canada, and Dr Maryanne Balkin, Consultant Anaesthetist, Alfred Health, Melbourne, Australia.

In this piece we discuss the latest news in medical publishing with Hugh Hemmings, editor-in-chief of the British Journal of Anaesthesia and Laszlo Vutskits, editor of Anesthesiology. We discuss the increasing volume of manuscripts being received by journals; the challenges of peer review, and initiatives to find and support new reviewers. Then we delve into the use of AI by authors and journals, and how this might influence publishing in the future. Presented by Andy Cumpstey and Kate Leslie on location at the Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine in Cairns, Australia, with their guests, Dr Hugh Hemmings, Joseph F. Artusio Jr. Professor and Chair, Department of Anesthesiology, Weill-Cornell Medicine, New York, USA, and Dr Laszlo Vutskits, Head of Pediatric Anesthesia at the Department of Anesthesiology, Pharmacology and Intensive Care at the University Hospital of Geneva, Switzerland.

In this episode, we dive into the game-changing drug sugammadex—a powerful agent that rapidly reverses neuromuscular blockade caused by rocuronium and vecuronium. We explore its unique mechanism of action, pharmacokinetics, and pharmacodynamics, along with how it differs from traditional reversal agents like neostigmine. You'll gain clarity on proper dosing strategies across populations, including pediatrics, obese patients, and those with renal impairment. We also break down important administration details, adverse effects, and drug interactions—especially the one that could compromise hormonal contraceptives. If you want to know how to avoid recurrent paralysis and make the most of this revolutionary medication in your clinical practice, stay tuned until the end.

Today's sponsor is Freed AI! Freed's AI medical scribe listens, transcribes, and writes notes for you. Over 15,000 healthcare professionals use Freed and you should too! Learn more here! On this episode of the Real Life Pharmacology Podcast, we cover minoxidil pharmacology, adverse effects, drug interactions, and much more. Minoxidil is a potent arterial vasodilator used in the treatment of hypertension and androgenetic alopecia. The route of administration greatly impacts the drug's safety profile. Oral minoxidil is typically reserved for refractory hypertension due to its strong systemic effects and associated risks. Topical formulations (2% or 5%) are widely used for hair regrowth, offering local benefits with minimal systemic absorption. Systemic minoxidil can result in fluid retention, tachycardia, and even pericardial effusion, often requiring co-administration with a diuretic and beta-blocker.

What's in our medicines? There are active ingredients, and there are excipients, which is everything else. From colorants to emulsifiers to adjuvants, excipients hide many horrors, and it's not even possible to know which ones are in your meds (or foods). Dairy that has been fortified with vitamins A & D also has seed oils and emulsifiers, but those things aren't on the label. The government database that should have all the information is full of errors. Polysorbate 80, a common emulsifier in food and drugs, is so complex that it hasn't been fully characterized, and is known to be cytotoxic generally, including being hemolytic—it breaks apart red blood cells. Meanwhile, Moderna's Covid “vax” has even more contaminants than previously recognized.*****Our sponsors:Masa Chips: Delicious chips made with corn, salt, and beef tallow—nothing else—in loads of great flavors. Go to http://masachips.com/DarkHorse, use code DarkHorse, for 20% off.Dose for your Liver: Tasty drink with milk thistle, ginger, dandelion & turmeric to support liver health. Save 30% of your first month at http://dosedaily.co/DarkHorse.Jolie: Beautiful showerheads that filter out the garbage without reducing water pressure. Go to http://jolieskinco.com/DarkHorse to get free shipping; free returns within 60 days.*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org*****Mentioned in this episode:FDA to ban petroleum-based dyes: https://www.fda.gov/news-events/press-announcements/hhs-fda-phase-out-petroleum-based-synthetic-dyes-nations-food-supplyMilk fortified with seed oils and Polysorbate 80: https://x.com/strong_sistas/status/1906085634357236222Abrantes et al 2016. An overview of pharmaceutical excipients: safe or not safe? Journal of pharmaceutical sciences, 105(7): 2019-2026: https://www.sciencedirect.com/science/article/abs/pii/S0022354916004470Betty Pezzimenti on DarkHorse, Nov 26, 2021: https://www.youtube.com/watch?v=-qA0wZD0iPwKinsella et al 2024. Inconsistent excipient listings in DailyMed: implications for drug safety. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(9): 6851-6854: https://link.springer.com/article/10.1007/s00210-024-03067-xRFK on Dr. Phil: https://www.youtube.com/watch?v=ZofNzZ8UoPkOn Food and Cooking by Harold McGee: https://amzn.to/3EFZBAj (commission earned)Sun et al 2017. Component-based biocompatibility and safety evaluation of polysorbate 80. RSC advances, 7(25): 15127-15138: https://pubs.rsc.org/en/content/articlepdf/2017/ra/c6ra27242hMore contaminants in the Moderna vaccine: https://x.com/kevin_mckernan/status/1917252562442506303Support the show

If you're struggling with chronic fatigue syndrome (ME/CFS) or debilitating tiredness that just won't go away, you're not alone—and you're not imagining things. Millions of people suffer from persistent fatigue that conventional medicine often fails to resolve. Fatigue and stress can make everyday tasks like working at a computer feel overwhelming, as seen in this image, which represents the experience of many with chronic fatigue syndrome (ME/CFS) At the Hedberg Institute, I'm always researching botanical compounds that support microcirculation, mitochondrial health, and immune regulation—all vital in restoring energy. That's why I formulated VascuSelect, a synergistic supplement that contains three powerful plant extracts: Ginkgo biloba, grape seed extract, and mango whole fruit powder. Let's dive into why Ginkgo biloba, in particular, stands out for those dealing with ME/CFS and how it works alongside other ingredients in VascuSelect to support your energy and vitality. An Important Study: Ginkgo Biloba for ME/CFS A recent paper published in Frontiers in Pharmacology (2022) titled “A Botanical Product Containing Cistanche and Ginkgo Extracts Potentially Improves Chronic Fatigue Syndrome Symptoms in Adults: A Randomized, Double-Blind, and Placebo-Controlled Study” sheds important light on Ginkgo's role in combating chronic fatigue. In this gold-standard clinical trial, 101 adults with ME/CFS received a botanical supplement combining Ginkgo biloba extract (120 mg/day) and Cistanche tubulosa extract (300 mg/day) or a placebo for 60 days. The results were impressive: Significant reductions in fatigue severity Improved physical performance and VO₂ max Enhanced antioxidant status and reduced oxidative stress markers Improved sleep quality and concentration Enhanced quality of life (QOL) and sexual life (SLQ) scores Decreased blood levels of lactic acid and ammonia (both fatigue biomarkers) What's particularly exciting is that Ginkgo biloba played a central role in this formulation. The authors noted that Ginkgo's flavonoids and terpenoids contribute to neuroprotection, vasodilation, and mitochondrial support, all of which are key areas of dysfunction in ME/CFS patients. This study confirms that Ginkgo biloba, known for enhancing blood flow and antioxidant activity, can play a central role in reducing the burdens of ME/CFS. How Ginkgo Biloba Helps Fight Fatigue Ginkgo biloba (standardized to 24% flavonol glycosides and 6% terpenes) is one of the most studied botanical extracts for circulatory and cognitive health. But its applications go far beyond brain support—especially for those with energy-depleting illnesses like ME/CFS. Ginkgo biloba is one of the oldest and most studied medicinal plants. It's been used for centuries in Traditional Chinese Medicine, but modern science is now validating its applications for conditions like ME/CFS, fibromyalgia, and Long COVID. 1. Improves Microcirculation Ginkgo biloba increases blood flow, especially in the small vessels of the brain and extremities. This is critical in ME/CFS, where impaired oxygen delivery to tissues can worsen fatigue. 2. Supports Mitochondrial Function Many people with ME/CFS experience dysfunctional mitochondria—the energy-producing engines of cells. Ginkgo has been shown to protect mitochondrial membranes and improve ATP production, helping the body generate more usable energy. 3. Reduces Oxidative Stress Oxidative stress is a hallmark of ME/CFS and contributes to inflammation, brain fog, and fatigue. Ginkgo's rich flavonoid profile helps neutralize free radicals and reduce oxidative damage. In the study mentioned above, participants taking Ginkgo and Cistanche showed significant increases in antioxidant enzymes like SOD and CAT. 4. Enhances Neurotransmitter Function Ginkgo biloba modulates neurotransmitters like dopamine, serotonin, and norepinephrine—chemicals that regulate mood,

On this episode, we discuss multiple sclerosis and describe its clinical presentations, types, and pathophysiology. We compare and contrast the efficacy, safety profiles, and clinical use of disease-modifying agents, supportive therapies, and monitoring strategies in the treatment of multiple sclerosis.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Today's sponsor is Freed AI! Freed's AI medical scribe listens, transcribes, and writes notes for you. Over 15,000 healthcare professionals use Freed and you should too! Learn more here! Prednisone is a commonly used medication for its antiinflammatory and immunosuppressive action. On this episode I discuss prednisone pharmacology, ADRs, and much more. In the episode, I discuss how prednisone affects the HPA system in the body. Cortisol production can be greatly impacted by long term use of prednisone. GI adverse effects can be problematic with oral prednisone which is why we often give this medication with food or milk. Hyperglycemia is a complication from the use of prednisone. I've commonly seen blood sugar spike by 50-100+ mg/dL due to this medication. Osteoporosis is a long term risk with the use of prednisone. Prednisone can also impact the benefits of vaccination. I discuss this in greater depth in the drug interactions portion of the podcast.

In this episode of the Friends of NPACE Podcast we are joined by our Executive Director, Terri Schmitt and COO, Josh Plotkin, as they discuss our upcoming Chicago Pharmacology Conference taking place April 7-9th! Our wonderful hotel the Intercontinental is a perfect location for this conference placing you right in the heart of Chicago. Get to enjoy the excellent sessions during the event and venture into the city to enjoy all Chicago has to offer each day. We look forward to seeing many of you on ground! Tune in every other Wednesday for new episodes of the Friends of NPACE Podcast on your favorite streaming platform (Spotify, Apple Music, YouTube, and Amazon Music).

Today's sponsor is Freed AI! Freed's AI medical scribe listens, transcribes, and writes notes for you. Over 15,000 healthcare professionals use Freed and you should too! Learn more here! On this episode of the Real Life Pharmacology Podcast, I cover linagliptin pharmacology, adverse effects, drug interactions, and much more. Linagliptin is a DPP-4 inhibitor used to help control blood sugar levels in adults with type 2 diabetes. It works by increasing the levels of incretin hormones, which stimulate insulin release and decrease glucagon levels in the blood. Linagliptin is usually taken once daily and can be used alone or in combination with other diabetes medications. Unlike some other diabetes drugs, linagliptin does not usually cause weight gain or low blood sugar (hypoglycemia) when used alone. Linagliptin should not be used with GLP-1 agonists as it works on a similar pathway as that medication class.

Learn more about INIM's Research Studies: https://www.nova.edu/nim/research-studies/index.html   Nathalie Sloane welcomes Dr. Theoharis Theoharides, Professor and Vice-Chair of Clinical Immunology, and Director of the Institute for Neuro-Immune Medicine-Clearwater. Together, they explore the often-overlooked health risks associated with natural disasters, including wildfires and severe flooding.   Dr. Theoharides examines the impact of California wildfires on mast cells and individuals with neurodegenerative conditions. He also discusses the toxins released by red tide along the West Coast, drawing comparisons to the wildfire.   He also outlines the long-term health consequences of environmental toxin exposure and mold from fires. This discussion underscores the importance of preventive strategies and highlights the critical role of nutrition in mitigating these risks.   Tune in to the Hope and Help for Fatigue and Chronic Illness Podcast – The Hidden Health Dangers of Natural Disasters   Sign up for the COVID-UPP Study: https://redcap.nova.edu/redcap/surveys/?s=RMEDJ7LKCX&_gl=1*1h830h7*_gcl_au*MTM2NDA0MTQyOS4xNzE1MDA0ODAy   If you are interested in joining a Gulf War Illness (GWI) trial, please complete the Recruitment Registry Form. https://redcap.nova.edu/redcap/surveys/?s=Y9YF8JJWJRK8HEKL%20&_gl=1*1fipp18*_gcl_aw*R0NMLjE3MDc5MTgwMzIuRUFJYUlRb2JDaE1JeWNyUXVfcXFoQU1WU1pCYUJSM3AyQWRBRUFBWUFTQUFFZ0s1NWZEX0J3RQ..*_gcl_au*MTg2NjgwMDQ4Ni4xNzA3MTQwNzgx     Dr. Theoharis Theoharides is a Professor, Vice Chair of Clinical Immunology, and Director at the Institute for Neuro-Immune Medicine-Clearwater, an Adjunct Professor of Immunology at Tufts School of Medicine, where he was a Professor of Pharmacology and Internal Medicine, and also the  Director of Molecular Immunopharmacology & Drug Discovery, and Clinical Pharmacologist at the Massachusetts Drug Formulary Commission (1983-2022). He received his BA, MS, MPhil, PhD, and MD degrees and the Winternitz Price in Pathology from Yale University and received a Certificate in Global Leadership from Tufts Fletcher School of Law and Diplomacy and a Fellowship at Harvard Kennedy  School of Government. He trained in internal medicine at New England Medical Center, which awarded him the Oliver Smith Award, “recognizing excellence, compassion, and service.” Dr. Theoharides has 485 publications (46,491 citations; h-index 106), placing him in the world's top 2% of most cited authors, and he was rated the worldwide expert on mast cells by Expertscape. He was inducted into the Alpha Omega Alpha National Medical Honor Society, the Rare Diseases Hall of Fame, and the World Academy of Sciences.   Website: https://www.drtheoharides.com  LinkedIn: linkedin.com/in/theoharis-theoharides-ms-phd-md-faaaai-67123735     NeuroProtek® - https://algonot.com/product/neuroprotek/?srsltid=AfmBOoq-k611ZodIzQCQZZChBkPJcawP0SasItDpp0RcBUpo27Ylh7XF   GentleDerm® - https://algonot.com/product-category/skin-health/ Nathalie Sloane is the Executive Director of the Institute for Neuro-Immune Medicine.   LinkedIn: https://www.linkedin.com/in/nathalie-sloane-90456625/  Instagram: https://www.instagram.com/nathaliesloane/   -------------------------------------------------------------------------------------------------   Enjoy our show? Please leave us a 5-star review on the following platforms so we can bring hope and help to others.   Apple Podcasts: https://podcasts.apple.com/us/podcast/hope-and-help-for-fatigue-chronic-illness/id1724900423   Spotify: https://open.spotify.com/show/154isuc02GnkPEPlWfdXMT   Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d   This podcast is brought to you by the Institute for Neuro-Immune Medicine. Learn more about us here.   Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM   #MedicalResearch #ChronicIllness #NeuroimmuneHealth #EnvironmentalToxins #MastCells #NaturalDisasters #Wildfires #RedTide #Flooding #ToxinExposure #Health #Wellness #MedicalPodcast #HealthPodcast

Meclizine is classified as a first-generation antihistamine. I discuss meclizine pharmacology, adverse effects, drug interactions, and much more. Meclizine is included on the Beers list due to its highly anticholinergic activity. Anticholinergic effects include constipation, dry eyes, dry mouth, urinary retention, and confusion. Sedation is an important adverse effect of meclizine. This adverse effect can be increased when used with other sedating medications such as opioids and benzodiazepines. Meclizine is primarily used for vertigo and motion sickness in clinical practice. The usual starting dose ranges between 12.5 to 25 mg. Meclizine is partially broken down by CYP2D6 so medications like bupropion can inhibit the breakdown of meclizine and lead to higher concentrations.

On this episode we review the 2025 Clinical Practice Guideline for the Pharmacologic Management of Adults with Dyslipidemia published by the American Association of Clinical Endocrinology. We compare and contrast the common medications used in the management of dyslipidemia and examine how these can be utilized based on the 13 updated recommendations found in the 2025 guidelines.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Matthew Baggott discusses the phenomenon of "losing the magic" with MDMA use, where frequent users experience diminishing therapeutic effects over time, likely due to decreased serotonin transporters in the brain; as well as N-Acetyl Cysteine (NAC) supplementation as a potential avenue for getting the magic back.  ... This is a clip from 'Entactogens, MDMA, and Bringing New Love Drugs To Market | Matthew Baggott ~ ATTMind Podcast 177' FULL INTERVIEW Listen on iTunes Listen on Spotify Watch in Video Read the show notes   SUPPORT THE PODCAST

“It's been known for quite a while that [KRAS] is a mutation that leads to cancer development, but for really over four decades, researchers couldn't figure out a way to target it. And so, it was often considered something that was undruggable. But all of this changed recently. So about four years ago, in 2021, we had the approval of the first KRAS inhibitor. So it's specifically a KRAS G12C inhibitor known as sotorasib,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the KRAS inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 11, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to KRAS inhibitors used for cancer treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Cancer Symptom Management Basics series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer Oncology Drug Reference Sheet: Adagrasib Oncology Drug Reference Sheet: Sotorasib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS course: Safe Handling Basics ONS video: What is the role of the KRAS biomarker in NSCLC? ONS Targeted Therapy Huddle Card ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets Lumakras® (sotorasib) manufacturer website Krazati® (adagrasib) manufacturer website UpToDate Lexidrug (formerly Lexicomp) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “If we look at specifically non-small cell lung cancer, this KRAS mutation is one of the most frequently detected cancer drivers or driver mutations. It's thought that about a quarter of cases of non-small cell lung cancer have this KRAS mutation, and it's usually a specific amino acid substitution that we see in non-small cell lung cancer, so what's known as KRAS G12C mutation.” TS 2:31 “Both of these agents, sotorasib and adagrasib, have the same mechanism of action. They bind to a pocket, very specifically on the KRAS G12C protein, and they lock it in an inactive state so that it can't cause that downstream uncontrolled signaling to happen. So they're kind of shutting down the signaling, and therefore you don't get that uncontrolled cell growth and proliferation.” TS 4:27 “Another big difference to point out, and one that is often used in clinical practice to differentiate when to use these agents, is specifically adagrasib is known to have activity in patients with metastatic non-small cell lung cancer that have active brain metastases. In the clinical trial, they included patients with active brain metastases, and they found that this drug has great [central nervous system] penetration. And so it may be considered the agent of choice in patients with brain metastases.” TS 7:19 “Other considerations—I think one of the big ones—is that there are a lot of drug interactions. Just specifically calling one out that I think is pretty impactful, is sotorasib has an interaction with acid-suppressing medications. So there is the recommendation to avoid [proton pump inhibitors] and H2 antagonists in patients receiving sotorasib. They can take antacids, but you would need to space those out from their dose of sotorasib.” TS 14:14 “This needs to be a collaborative endeavor to make sure these patients are monitored appropriately. We are putting a lot of responsibility on the patients with all of this. So, again, completely administered generally in the home setting, a lot of monitoring, a lot of adverse effects, need for reporting and management—so there's a lot happening here. And it takes a team to accomplish this and to do it right. And I firmly believe that this is often a collaborative effort between our pharmacy and oncology nursing teams to make this happen. Working together to ensure outreach to patients—I think that patients are often more successful with these medications with early identification of toxicities when we're doing scheduled outreach.” TS 19:44

In this episode, we dive deep into the basics of anesthesia pharmacology—perfect for ICU nurses starting CRNA school or senior residents needing a solid refresher. We break down foundational topics like pharmacodynamics, pharmacokinetics, and pharmacogenomics, and explain why understanding physiology is key to mastering pharmacology. You'll learn about drug targets like GABA and NMDA receptors, and the real mechanisms behind anesthetics, opioids, local anesthetics, and muscle relaxants. We also walk through “top drawer drugs” in the OR, including quick quizzes to reinforce your understanding of real-time drug decisions—like when to choose ephedrine over phenylephrine. This is a science-heavy episode, but one that sets the groundwork for more advanced content.

In this episode of PT Snacks podcast, host Kasey explores the importance of understanding common hypertension and cholesterol medications encountered in outpatient orthopedic settings. Kasey discusses the effects of beta blockers, ACE inhibitors, ARBs, calcium channel blockers, diuretics, and statins on patients' response to exercise. The episode covers potential side effects, red flags, and practical tips for physical therapists, highlighting the significance of a holistic approach to patient care. Additional resources and special offers through MedBridge are also mentioned.00:00 Welcome to PT Snacks Podcast00:56 Importance of Pharmacology in PT02:09 Understanding Blood Pressure Medications04:31 Cholesterol Medications and Their Effects05:34 Red Flags and Patient Management Tips06:51 Additional Resources and ConclusionRelevant MedBridge Courses1. Exercise and Drug Interactions by Kenneth L. Miller - Overview: Understand how various medications interact with exercise. Covers physiology, drug metabolism, and exercise prescription. 2. Pharmacology for Rehabilitation: Considerations for the Aging Adult by Andrew Opett - Overview: Explores the effects of drugs like antihypertensives and statins, especially in older adults.Support the showWhy PT Snacks Podcast?This podcast is your go-to for bite-sized, practical info designed for busy, overwhelmed Physical Therapists and students who want to build confidence in their foundational knowledge without sacrificing life's other priorities. Stay Connected! Never miss an episode—hit follow now! Got questions? Email me at ptsnackspodcast@gmail.com or leave feedback HERE. Join the email list HERE On Instagram? Find unique content at @dr.kasey.hankins! Need CEUs Fast?Time and resources short? Medbridge has you covered: Get over $100 off a subscription with code PTSNACKSPODCAST: Medbridge Students: Save $75 off a student subscription with code PTSNACKSPODCASTSTUDENT—a full year of unlimited access for less!(These are affiliate links, but I only recommend Medbridge because it's genuinely valuable.) Optimize Your Patient Care with Tindeq Looking for a reliable dynamometer to enhance your clinical measurements? Tindeq ...

In this episode, I discuss amphetamine/dextroamphetamine pharmacology, adverse effects, drug interactions, and much more. Stimulants like Adderall are well known to cause insomnia. This adverse effect can be affected by the timing of the dose. Lack of growth and poor appetite are two important things to monitor in pediatric patients taking Adderall. Changes in the pH of the stomach/gut can alter the absorption of Adderall. I discuss this in greater detail in this podcast episode. Cardiovascular monitoring is essential with the use of stimulants like Adderall. Pulse and heart rate are two important vital signs to assess.

SOCK method quiz/cheatsheets/resources at: https://nursing.com/sock   In this raw and revealing episode, Jon Haws, RN, shares his personal journey from pharmacology nightmare to nursing confidence. With vulnerability and humor, Jon recounts his 3 AM study sessions surrounded by scattered flashcards and energy drinks, feeling like a failure as he struggled to memorize endless drug facts that wouldn't stick. When a simple clinical question about Zofran administration left him frozen, Jon discovered a breakthrough approach that transformed his nursing education. Through heartfelt storytelling and evidence-based insights, Jon introduces the SOCK Method (Side Effects, Organs, Classes/Considerations/Cards, Know) - a framework that replaces overwhelming memorization with meaningful connections and clinical reasoning. This episode features Jon's signature blend of nursing wisdom, personal struggle, and practical solutions, including a weekly study plan and Nurse Blake-inspired humor that will have you laughing through your pharmacology tears. Whether you're currently drowning in drug cards or looking to strengthen your medication knowledge, Jon's compassionate guidance offers a lifeline for every nursing student who's ever wondered: "Is there something wrong with me?" Join the nursing family that's putting on their SOCKs and walking confidently toward pharmacology mastery.

Send us a textDelirium in the NICU is an under-recognized and under-assessed challenge. In this episode of The Incubator Podcast, Ben and Daphna sit down with Dr. Karishma Rao and clinical pharmacist Alex Oschman from Children's Mercy Hospital to explore the complexities of neonatal delirium. Drawing on their collaborative work and recent publication in Frontiers in Pharmacology, they unpack the nuances of distinguishing delirium from pain, agitation, withdrawal, and sedation—particularly in medically complex, long-stay infants.The conversation highlights the limitations of current assessment tools, such as the CAPD (Cornell Assessment of Pediatric Delirium), and the barriers to implementation in the NICU setting. The team shares practical strategies, including modifying pain and withdrawal protocols, minimizing deliriogenic medications like benzodiazepines and opioids, and emphasizing non-pharmacological interventions like early mobility, sleep hygiene, and environmental optimization.They also discuss pharmacologic options when needed, such as the selective use of atypical antipsychotics like quetiapine or risperidone, and raise critical questions about how developmental care might reduce the need for sedation altogether. This episode is a call to action for NICU teams to better understand, assess, and address delirium in our most vulnerable patients through collaborative, multidisciplinary care.  As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

On this episode, we evaluate current guidelines and evidence-based treatment strategies for managing menstruation-related disorders. We compare and contrast the efficacy, safety profiles, and appropriate use of hormonal and non-hormonal treatment options as well as patient monitoring in addressing menstruation-related disorders.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Today's sponsor is Freed AI! Freed's AI medical scribe listens, transcribes, and writes notes for you. Over 15,000 healthcare professionals use Freed and you should too! Learn more here! Benazepril is an ACE inhibitor used to treat hypertension by blocking the conversion of angiotensin I to angiotensin II, reducing vasoconstriction. Combining benazepril with potassium-sparing diuretics or potassium supplements increases the risk of hyperkalemia due to aldosterone suppression. Common side effects of benazepril include dry cough, hyperkalemia, and hypotension due to its effect on the renin-angiotensin-aldosterone system. Benazepril can be prescribed alone or in combination with other antihypertensive agents, such as diuretics or calcium channel blockers, to enhance blood pressure control. Benazepril has a long duration of action, allowing for once-daily dosing, which improves patient adherence and convenience in hypertension management.

Episode: 1341 A view of physiology in 1872 -- not that long ago.  Today, let's look at medicine when my grandfather was young.

Today's sponsor is Freed AI! Freed's AI medical scribe listens, transcribes, and writes notes for you. Over 15,000 healthcare professionals use Freed and you should too! Learn more here! On this podcast episode, I cover loratadine pharmacology, adverse effects, drug interactions, and much more. Loratatdine is a second generation antihistamine. It has a lower incidence of central nervous system adverse effects compared to first-generation antihistamines like diphenhydramine. Loratadine dosing varies in pediatric patients and those with renal impairment. I get into the details on this podcast episode. Drug interactions aren't common with loratadine but I discuss a few that may be clinically significant.

My guest is Stuart McMillan, a renowned track and field coach who has trained dozens of Olympic medalists, professional athletes, and team coaches across a diverse range of sports. We discuss how to use plyometric work to improve mobility, strength, posture, and overall health. We emphasize the enormous benefits of skipping—a form of plyometrics—for joint health, aerobic conditioning, and coordination, as well as its advantages for people of all ages and fitness levels. We also explore the expressive nature of human movement, highlighting how certain movements reveal and can evolve one's unique personality and abilities. Stu explains how resistance training, skipping, and striding can improve movement efficiency in all aspects of life. Anyone who exercises, as well as serious athletes, will benefit immensely from Stu McMillan's knowledge of human mechanics and the practical tools he generously shares in this discussion. Read the full episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Our Place: https://fromourplace.com/huberman Wealthfront**: https://wealthfront.com/huberan Helix Sleep: https://helixsleep.com/huberman Function: https://functionhealth.com/huberman **This experience may not be representative of the experience of other clients of Wealthfront, and there is no guarantee that all clients will have similar experiences. Cash Account is offered by Wealthfront Brokerage LLC, Member FINRA/SIPC. The Annual Percentage Yield (“APY”) on cash deposits as of December 27,‬ 2024, is representative, subject to change, and requires no minimum. Funds in the Cash Account are swept to partner banks where they earn the variable‭ APY. Promo terms and FDIC coverage conditions apply. Same-day withdrawal or instant payment transfers may be limited by destination institutions, daily transaction caps, and by participating entities such as Wells Fargo, the RTP® Network, and FedNow® Service. New Cash Account deposits are subject to a 2-4 day holding period before becoming available for transfer. Timestamps 00:00:00 Stuart McMillan 00:02:27 Running, Sprinting, Event Distances 00:09:01 Sponsors: Our Place & Wealthfront 00:12:13 Natural Sprinters, Kids, Sports Specialization 00:17:00 Athletes, Identity, Race Selection 00:23:38 Walking to Sprinting, Gait Patterns, Tool: Flat-Foot Contact 00:30:35 Visual Focus, Body Position, Running, Lifting Weights 00:36:00 Tool: Skipping & Benefits 00:42:18 Sponsors: AG1 & Helix Sleep 00:45:01 Tools: Skipping, Beginners, Jogging Incorporation 00:49:50 Transition Points, Tool: Skipping, Maximum Amplitude 00:53:03 Concentric & Eccentric Phases, Running 00:55:32 Transitioning to Striding, Posture, Center of Mass 01:03:11 Older Adults, Eccentric Control, Tool: Skipping 01:08:00 Naming Importance & Public Health; Skipping, Plyometrics 01:12:18 Sponsor: Function 01:14:06 Cross-Body Coordination, Rotation, Gaits; Phones & Posture 01:22:27 Expression Through Movement, Playfulness, Confidence 01:28:53 Being Yourself, Expression, Essence & Movement 01:36:39 Connecting with Movement, Building Cues, Mood Words 01:45:05 Pressure & Peace; Exercise, Movement & Age 01:51:39 Music, Art, Rhythm, Coaching; Soccer, Greatest Players & Countries 02:00:25 White & Black Athletes, Genetics, Environment 02:08:27 Running Form, Tools: High Knees, Stiff Springs, Hip Extension 02:17:21 Skipping Rope, Aging; Protocols & Rigidity, Principles Alignment 02:22:12 Resistance Training to Improve Movement, Sprinting Kinetics, Individualization 02:32:29 Transferring Weight Room to Track, Staggered Stance, Stretching 02:36:52 Performance-Enhancement, Elite Athletes, Androgen, Reputation 02:46:45 Testosterone Replacement Therapy (TRT), Age; Pharmacology vs. Training 02:52:14 Single Physical Metric & Sprinting; Pressure & Peace 02:58:34 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter

On this episode, we evaluate current guidelines and evidence-based treatment strategies for managing plaque psoriasis, including topical, systemic, and biologic therapies. We compare and contrast the efficacy, safety profiles, and appropriate use of different treatment modalities and patient monitoring in the management of plaque psoriasis. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Modafinil (Provigil) is a CNS stimulant medication. I cover modafinil pharmacology, adverse effects, drug interactions, and much more on this podcast episode. You should be aware that modafinil is a Schedule 4 controlled substance so it does carry a risk of dependence and addiction. Modafinil can cause CYP3A4 induction and lead to lowering the concentrations of many medications. This includes antiepileptic agents and oral contraceptives. The most common adverse effects of modafinil include ramping up the body and causing symptoms such as anxiety and insomnia. Cardiovascular changes are a risk with modafinil as this medication can contribute to hypertension and tachycardia.